Donovan Jennifer L, DeVane C Lindsay, Malcolm Robert J, Mojsiak Jurij, Chiang C Nora, Elkashef Ahmed, Taylor Robin M
Laboratory of Drug Disposition and Pharmacogenetics, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA.
Clin Pharmacokinet. 2005;44(7):753-65. doi: 10.2165/00003088-200544070-00006.
To determine if modafinil, a putative treatment for cocaine dependence, influences the pharmacokinetics of intravenous cocaine in otherwise healthy cocaine-dependent volunteers.
Cocaine 20 or 40 mg was administered intravenously on consecutive days over 1 minute at baseline and after modafinil administration at each of two dosages of 400 and 800 mg/day for 7 days.
Twelve subjects completed the clinical protocol. Compared with baseline, the cocaine peak plasma concentration was decreased after both the 20 and 40 mg cocaine infusions, but the reduction was only statistically significant after the 40 mg cocaine infusion (p < 0.01 after modafinil 400 mg/day; p < 0.05 after modafinil 800 mg/day). The area under the cocaine plasma concentration-time curve from 0 to 180 minutes (AUC180) was significantly decreased by modafinil administration (p < 0.01 and p < 0.001 for modafinil 400 and 800 mg/day, respectively, for the cocaine 20mg dose; p < 0.001 for the cocaine 40 mg dose at both modafinil levels). There were no significant changes in total AUC, clearance or elimination half-life of cocaine.
This study did not find evidence for a harmful pharmacokinetic interaction between modafinil and cocaine. In contrast, long-term administration of modafinil significantly decreased systemic exposure to cocaine during the first 180 minutes following intravenous cocaine administration.
确定莫达非尼(一种用于治疗可卡因依赖的假定药物)是否会影响健康的可卡因依赖志愿者静脉注射可卡因后的药代动力学。
在基线时以及每天服用400毫克和800毫克两种剂量的莫达非尼,持续7天后,连续两天在1分钟内静脉注射20毫克或40毫克可卡因。
12名受试者完成了临床方案。与基线相比,20毫克和40毫克可卡因输注后,可卡因的血浆峰值浓度均降低,但仅在40毫克可卡因输注后,这种降低具有统计学意义(每天服用400毫克莫达非尼后p<0.01;每天服用800毫克莫达非尼后p<0.05)。服用莫达非尼后,0至180分钟的可卡因血浆浓度-时间曲线下面积(AUC180)显著降低(对于20毫克剂量的可卡因,每天服用400毫克和800毫克莫达非尼时,p分别<0.01和p<0.001;对于两种莫达非尼水平下的40毫克剂量可卡因,p<0.001)。可卡因的总AUC、清除率或消除半衰期没有显著变化。
本研究未发现莫达非尼与可卡因之间存在有害药代动力学相互作用的证据。相反,长期服用莫达非尼可显著降低静脉注射可卡因后最初180分钟内可卡因的全身暴露量。